Thursday, August 17, 2017

Context Therapeutics Initiates Collaborations With Three Leading Research Partners On The Biology Of Sigma1

Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis, and neurodegenerative disease, today announced that the company has entered into agreements with three research partners.

Details:
www.businesswire.com/news/home/20170817005060/en/Context-Therapeutics-Initiates-Collaborations-Leading-Research-Partners

No comments:

Post a Comment